01 Dec 2023

Precision Surgery Improving Outcomes for Cancer Patients

FluoGuide is a clinical-stage biotech company, elevating precision surgery with FG001, illuminating cancer cells during surgery to enhance outcomes for patients

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

LatestPress & news

29 Nov 2023 FluoGuide A/S publishes interim report for the period January – September 2023 News English Regulatory Listing Regulation Report Interim Q3 IR
13 Nov 2023 FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer News Corporate Action Other English Regulatory MAR IR

FluoGuideAn introduction

FluoGuide develops drugs for maximizing surgical outcomes by making cancer fluorescent.

Successful application of FluoGuide’s products will lower system-wide healthcare costs because it will reduce the recurrence of cancer and lessen general surgical complications. Thereby, patients will require fewer readmissions to hospitals.

Project StatusRapidly progressing pipeline

FluoGuide’s pipeline consists of product candidates that can potentially make most solid cancers fluorescent. We advance our pipeline at a rapid pace for the benefit of patients with cancer, society, and our shareholders. FluoGuide’s lead-product, FG001, is in phase IIa clinical development targeting patients undergoing surgical removal of high-grade glioma. FluoGuide is also developing FG001 in lung cancer and Head & Neck cancer.


Phase I
Phase II
Phase III
Aggressive Brain cancer
Next milestone: Consolidated plans
Head and Neck cancer
Next milestone: Consolidated plans
Lung cancer
Next milestone: Consolidated plans
Follow-on pipeline
Next milestone: CTA submission
Photothermal therapy
Next milestone: Plans and timelines

FluoGuideCalendar & events

Latest presentations

14 November 2023

Redeye interview on topline data from ph IIb in aggressive brain cancer

10 November 2023

Interview with Dansk Aktionærforeningen (in Danish)

Subscribe for newsletter